India's second largest IT firm Infosys Ltd Wednesday unveiled a cloud-based solution to speed up clinical trials and lower drug development costs.
"The solution helps life sciences companies to accelerate clinical trials by driving greater collaboration between pharmaceutical firms and contract research organisations," the global software major said in a statement here.
As a new version of the clinical trial supply management, the cloud solution will improve productivity of drug development process and ensure timely supply of drugs to patients at lower cost.
"Enterprises using our solution will be able to price their drugs competitively as the software application enables real-time collaboration and helps transform their research and development (R&D) cost model," Infosys' global head for life sciences and services Manish Tandon said in the statement.
As the new version is cloud-based, the solution offers tools to manage the entire supply chain of clinical trials, covering demand and supply, planning and distribution across R&D sites.
A beta version of the solution is in use for clinical trials at some of the global pharma firms in Europe and the US.
"The software product will enable pharma companies to respond faster to changes in demand, based on enrollment and patient turnaround during trials as it can be integrated with enterprise resource planning (ERP) systems, incorporating business processes," Tandon said.
Being cloud-based, the solution will be offered on pay-per-use basis, which will help pharma and biotech firms and contract research units to avoid investing in and managing expensive IT infrastructure for clinical trials.
"With mobility-enabled transactions and remote access capabilities, the solution facilitates real-time data entry for faster decision making," Tandon noted.
The company is showcasing the solution at the three-day 'Sapphire Now' conference being held at Orlando in the US since Tuesday.
"Clinical trials are growing in scale and complexity, driving a need for business processes and systems that integrate the end-to-end activities, decisions and information across business functions," the statement said quoting from a recent Gartner report.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
